HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 24, No. 09, September 2020 – 3D Technology: Additive Manufacturing Applications and Prospects       » Results of CD30 CAR-T Cell Therapy Trial Shows Promise for Hodgkin Lymphoma Patients       » Emerging Technologies and Innovations amid a Global Pandemic       » Monitoring COVID-19 Patients with AI-powered Platform       » Singapore Researchers Devise a Rapid COVID-19 Test Kit for the Detection of Neutralising Antibodies (NAbs) Against SARS-CoV-2       » Novel Ventilator Conceptualized by Singapore Clinicians Provides Efficient and Personalized Breathing Support for COVID-19 patients      
Vol 22, No. 08, August 2018   |   Issue PDF view/purchase
EDITOR'S LETTER
Regeneration: from fighting to building

Regenerative medicine is an area of medicine with the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions today that are beyond repair. It is a branch of biomedical translational research that “replaces or regenerates human cells, tissues or organs, to restore or establish normal function”.

It involves the use of stem cells (cell therapies) and transplantation of in vitro grown organs and tissues (tissue engineering). Blood transfusions and bone marrow transplants are the most common forms.

What distinguishes regenerative medicine apart from traditional drugs is that the latter mostly treat symptoms, whereas the former aims to treat the root cause of a patient's condition by replacing lost cells or organs, or by fixing a faulty gene.

In a report published in 2017 in The Lancet, scientists observed that the number of regenerative medicine treatments in medical use today is very low. Only a handful of breakthroughs made it to patients, and private clinics are cashing in on patients' desperate search for treatments by offering unproven therapies. This combination of poor quality science, unclear funding models, unrealistic hopes and unscrupulous private clinics threatens regenerative medicine's social license to operate.

Experimental regenerative medicine treatments are being carried out in animals. At the Veterinary Health Center at Kansas State University, it is offering platelet-rich plasma and animal stem cell therapies for horses suffering from osteoarthritis, tendon injuries and ligament tears. The initial studies are promising, however the professors warned that there needs to be validated scientific protocols and sound clinical decision-making to minimise the variables associated with the actual stem cells used in each horse.

In another report published in 2018 by Stem Cells Translational Medicine, researchers have developed a simple, minimally invasive, effective way to treat osteoarthritis in dogs, using adipose (fat) tissues.

These studies in animals underscores the need to transition this technology to human clinical trials.

Despite the successes in these new therapies studies, regenerative medicine treatments have not entered mainstream medical practice. The Lancet report suggests that "the potential exists to substantially reduce the burden of disease for some common conditions (e.g. stroke, heart disease, progressive neurological conditions, autoimmune diseases, and trauma)".

Let’s cell-ebrate this advancement of science and technology, enhancing the lives of people and animals around the world.


Lim Guan Yu
APBN Editor
You can reach me at gylim@wspc.com

 

You can always access all APBN's issues on our website: www.asiabiotech.com.
Check us out at Facebook @Asia Pacific Biotech News, Instagram @asiabiotech, or follow us on Twitter @asia_biotech.

 

NEWS CRUNCH  
news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season
news PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products
news Singapore Biomedical Company Appointed as a Certified Service Provider by 10x Genomics
news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy